Citalopram plus reboxetine in treatment-resistant obsessive-compulsive disorder

Leonardo F. Fontenelle, Mauro V. Mendlowicz, Euripedes C. Miguel, Marcio Versiani

Research output: Contribution to journalArticleResearchpeer-review

6 Citations (Scopus)


While serotonin reuptake inhibitors (SRIs) are the first-line treatment of obsessive-compulsive disorder (OCD), as many as 40-60% of patients fail to respond to adequate trials with these drugs. In this study, we describe the case of a patient with an SRI-resistant OCD who was successfully treated with a combination of citalopram (a selective SRI) and reboxetine (a selective noradrenaline reuptake inhibitor (SNRI)). This report suggests that future studies accessing the efficacy of the SRI-SNRI combination in treatment resistant OCD are needed.

Original languageEnglish
Pages (from-to)57-59
Number of pages3
JournalThe World Journal of Biological Psychiatry
Issue number1
Publication statusPublished - 7 Jun 2005
Externally publishedYes


  • Citalopram
  • Obsessive-compulsive disorder
  • Reboxetine

Cite this